The antigenic link between thyroid autoimmunity and breast cancer

Muller, Ilaria; Barrett-Lee, Peter

doi:10.1016/j.semcancer.2019.05.013

Cited by 20 publications

(27 citation statements)

References 237 publications

(310 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, peritumoral lymphovascular invasion rate was lower (17.8%), and there was no significant difference in terms of peritumoral lymphovascular invasion between the groups. Normal and neoplastic breast epithelial cells express thyroid hormone receptors and thyroid hormones show an in vitro tumor-promoting effect .In particular, they induce estrogen-like differentiation and lobular growth of breast tissue [17] .…”

Section: Discussionmentioning

confidence: 99%

Less Pathological Axillary Involvement is Observed in Breast Cancer Patients with Autoimmune Thyroid Disease

Yalçın¹,

Cosar²,

Güngüneş³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Autoimmune thyroid disease is more frequently observed in breast cancer patients. There are not enough studies showing the prognostic significance of this association in terms of breast cancer. The aim of this study was to determine the breast cancer molecular subgroup frequency and to examine the relationship between autoimmune thyroid disease and the breast cancer in terms of prognosis and predictive factors. Methods: One hundred and one patients have been included to study. They have been divided into subgroups according to molecular classification. The patients with high serum anti-thyroid peroxidase levels were considered positive for autoimmune thyroid disease. Prognostic and predictive parameters [tumor stage, tumor size, axillary lymph node involvement, histologic grade, lymphovascular , perineural invasion, hormone receptor status, HER2 (Human Epidermal Growth Receptor 2) over expression] were compared between breast cancer patients with autoimmune thyroid disease and those patients without autoimmune thyroid disease. Results: The prevalence of thyroid autoimmunity was 23.8% (n = 24) in breast cancer patients. The axillary lymph node involvement in autoimmune thyroid disease positive breast cancer patients was lower than autoimmune thyroid disease negative patients (37.5% versus 61% respectively, p = 0.043). There were no significant differences between the two groups in terms of other prognostic parameters. More importantly, there was a significantly negative correlation between anti thyroid peroxidase levels and axillary lymph node involvement in patients (r= -0.245, p=0.014). Conclusion: Positive axillary lymph nodes, have been found to be lower in breast cancer patients accompanied by autoimmune thyroid disease. This result supports the view that thyroid autoimmunity is a positive prognostic factor in terms of breast cancer. The mechanism through which it is effective should be examined in new studies. Trial registration: A written approval was granted by the Kirikkale University, Faculty of Medicine, Clinical Research Ethics Committee through the 01/09 Numbered and 19.01.2016 Dated Decision in order to conduct this study. Keywords: Thyroid autoimmune, breast cancer, prognostic factors

show abstract

Section: Discussionmentioning

confidence: 99%

Less Pathological Axillary Involvement is Observed in Breast Cancer Patients with Autoimmune Thyroid Disease

Yalçın¹,

Cosar²,

Güngüneş³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…For example, Liu et al have recently shown that TPOAbs level is associated with cardiometabolic risk factors in non-obese euthyroid individuals [56]. Another widely discussed issue is the connection between thyroid antibodies and cancer [57][58][59]. Some authors reported positive association between anti-thyroid autoantibodies (TgAbs and/or TPOAbs) titers and papillary thyroid cancer (PTC) risk and severity [60,61], however, others question the role of thyroid autoimmunity in thyroid cancer [62].…”

Section: Clinical Utility Of Tpoabs Testingmentioning

confidence: 99%

“…Some authors reported positive association between anti-thyroid autoantibodies (TgAbs and/or TPOAbs) titers and papillary thyroid cancer (PTC) risk and severity [60,61], however, others question the role of thyroid autoimmunity in thyroid cancer [62]. The large majority of studies reported higher frequency of thyroid antibodies, especially TPOAbs, in breast cancer patients in comparison with healthy controls [59]. Several reports showed a more favorable outcome of breast cancer in TPOAbs-positive patients than in TPO-negative patients, nevertheless the protective role of TPO-driven autoimmunity continues to be debated [59,63].…”

Section: Clinical Utility Of Tpoabs Testingmentioning

confidence: 99%

“…The large majority of studies reported higher frequency of thyroid antibodies, especially TPOAbs, in breast cancer patients in comparison with healthy controls [59]. Several reports showed a more favorable outcome of breast cancer in TPOAbs-positive patients than in TPO-negative patients, nevertheless the protective role of TPO-driven autoimmunity continues to be debated [59,63]. One hypothesis suggested shared antigen(s) between thyroid and breast tissues, which trigger immune reaction in thyroid autoimmunity and breast cancer.…”

Section: Clinical Utility Of Tpoabs Testingmentioning

confidence: 99%

See 1 more Smart Citation

Thyroid Peroxidase Revisited – Whatʼs New?

et al. 2019

View full text Add to dashboard Cite

ABstr Ac tThyroid peroxidase (TPO) is an enzyme that participates in thyroid hormone biosynthesis. TPO is also a major autoantigen in autoimmune thyroid diseases (AITD). In this review, we summarize the latest developments in the field of TPO research. We present the current understanding of immunodominant serologic determinants, frequency of TPO-specific autoantibodies in the population, as well as genetic and environmental factors contributing to their development. Moreover, we report recent progress in the clinical utilities of TPO autoantibody testing, including thyroid dysfunctions and extra-thyroidal disorders. *Professor Emeritus.

show abstract

“…T hyroid and breast tissue share some common molecular markers. Both normal and pathologic breast tissues exhibit high concentrations of sodiumiodide symporter, peroxidase, and deiodinase, indicating the active involvement of breast tissues in iodine metabolism (1,2). There is considerable conflicting literature on the relationship between thyroid and breast disorders (3)(4)(5)(6)(7)(8).…”

Section: Introductionmentioning

confidence: 99%

Thyroid dysfunctions and autoimmunity in breast cancer patients: a prospective case-control study

Jha

Mishra

Yadav

et al. 2020

Archives of Endocrinology and Metabolism

View full text Add to dashboard Cite

Objective: The relationship of thyroid dysfunction and autoimmunity with breast cancer (BC) continues to be contentious. The primary aim of this study was to estimate the prevalence of thyroid dysfunctions and autoimmunity in BC patients, and the secondary aims were to investigate the relationship of thyroid dysfunction with the clinicopathological profile of and therapy received by BC patients. Materials and methods: This was a single-center prospective case-control study (March 2015-May 2017). Women with BC (n = 191), age-matched healthy controls (n = 166) and malignant controls (patients with cervical cancer, n = 87) were enrolled. Basal serum free thyroxin (fT4), thyrotropin (TSH) and anti-thyroid peroxidase (TPO) antibody levels were measured in all three groups; fT4, TSH and TPO measures were repeated after chemotherapy and at the 1-year follow-up (one year after diagnosis) in the BC patients. Results: The prevalence of overall hypothyroidism and autoimmunity (p = 0.106) did not differ significantly between the three groups, but the rate of clinical hypothyroidism was significantly higher in the BC group than in the healthy control group and the malignant control group (12.2% vs. 3.0% vs. 4.6%, respectively; p = 0.001). BC patients had significantly lower mean basal TSH concentrations than the healthy controls (p = 0.017). The postchemotherapy TSH concentrations were significantly lower (p = 0.001), and the fT4 concentrations were higher, albeit not significantly (p = 1.00), than the respective basal concentrations. The reverse was true for the follow-up values, in which the TSH (p = 1.00) values were higher and the fT4 (p = 0.03) concentrations were lower than the respective basal concentrations. An additional 6% of the BC patients developed clinical hypothyroidism during follow-up. Hypothyroid (p = 0.02) and TPO-positive (p = 0.004) patients had significantly smaller tumors, but their other clinicopathological features were comparable to those without thyroid dysfunction. Conclusions: The prevalence of clinical hypothyroidism requiring thyroxine replacement was significantly high in BC patients and increased further during follow-up. Hence, BC patients should be considered a high-risk group that should receive routine screening for hypothyroidism.

show abstract

The antigenic link between thyroid autoimmunity and breast cancer

Cited by 20 publications

References 237 publications

Less Pathological Axillary Involvement is Observed in Breast Cancer Patients with Autoimmune Thyroid Disease

Less Pathological Axillary Involvement is Observed in Breast Cancer Patients with Autoimmune Thyroid Disease

Thyroid Peroxidase Revisited – Whatʼs New?

Thyroid dysfunctions and autoimmunity in breast cancer patients: a prospective case-control study

Contact Info

Product

Resources

About